Candesartan Doesn't Prevent Trastuzumab Cardiotoxicity

This article originally appeared here.
Share this content:
Candesartan Doesn't Prevent Trastuzumab Cardiotoxicity
Candesartan Doesn't Prevent Trastuzumab Cardiotoxicity

FRIDAY, June 24, 2016 (HealthDay News) -- In patients with early breast cancer, candesartan does not protect against trastuzumab-related cardiotoxic effects, according to a study published online June 23 in JAMA Oncology.

Annelies H. Boekhout, Ph.D., from the Netherlands Cancer Institute in Amsterdam, and colleagues conducted a randomized placebo-controlled trial involving 210 women with early breast cancer testing positive for human epidermal growth factor receptor 2. Patients were randomized to 78 weeks of candesartan (32 mg/day) or placebo (103 in each group); treatment started on the same day as the first trastuzumab treatment.

The researchers found that 36 patients manifested at least one of the two primary cardiac end points. Compared with the placebo group, there were 3.8 percent more cardiac events in the candesartan group (P = 0.58), with 19 and 16 percent in each group, respectively. The two-year cumulative incidence of cardiac events in the candesartan and placebo groups was 0.28 and 0.16, respectively (P = 0.56). Candesartan had no effect on changes in the N-terminal of the prohormone brain natriuretic peptide and high-sensitivity troponin T values; there was no correlation for these biomarkers with significant changes in left ventricular ejection fraction.

"The findings do not support the hypothesis that concomitant use of candesartan protects against a decrease in left ventricular ejection fraction during or shortly after trastuzumab treatment in early breast cancer," the authors write.

The study was supported by unrestricted financial contributions from Roche; AstraZeneca provided the study drug and placebo.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Hospitals Vary Widely in Moving Stroke Patients to Comfort Care

Hospitals Vary Widely in Moving Stroke Patients to ...

Doctors more apt to suggest it sooner for older, white, female, and uninsured patients

Peri-Op IV Acetaminophen May Reduce Post-Op Pain in Sinus Sx

Peri-Op IV Acetaminophen May Reduce Post-Op Pain in ...

Reduction in immediate postoperative pain after endoscopic sinus surgery, but results inconclusive

Location of Body Fat Can Indicate Obesity-Related Cancer Risk

Location of Body Fat Can Indicate Obesity-Related Cancer ...

Where fat is carried is as strong a predictor as BMI, researchers suggest

is free, fast, and customized just for you!

Already a member?

Sign In Now »